Endomed s.r.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
At Endomed s.r.o. in Kosice, clinical research in Digestive System Diseases focuses mainly on inflammatory bowel disease, including Crohn’s disease, ulcerative colitis, coeliac disease, and related gastrointestinal disorders. The trials are designed to test new treatments, compare treatment options, and better understand how these conditions affect the digestive tract.
- Studies in Crohn’s disease and ulcerative colitis aimed at improving symptom control and long-term disease management
- Research on coeliac disease and eosinophilic esophagitis exploring immune-related gut inflammation and mucosal healing
- Clinical evaluation of new therapies for inflammatory bowel disease to measure remission, healing, and overall treatment effectiveness
Overall, this therapeutic area is centered on finding safer and more effective options for people living with chronic gastrointestinal inflammation and immune-driven digestive disorders.
Immune System Diseases
The Immune System Diseases research portfolio at Endomed s.r.o. includes trials for conditions where the immune system drives ongoing inflammation, especially Crohn’s disease, ulcerative colitis, and eosinophilic esophagitis. These studies aim to improve how immune-targeted treatments work and to assess whether they can reduce inflammation and support lasting disease control.
- Trials in moderately to severely active Crohn’s disease assessing new immune-based therapies for remission and response
- Research in moderately to severely active ulcerative colitis focused on treatment effectiveness, maintenance of benefit, and symptom relief
- Studies in eosinophilic esophagitis and non-responsive celiac disease examining immune activity in the gut and esophagus
These projects reflect a strong emphasis on immune-mediated disease, with the goal of advancing targeted approaches that may better match the needs of patients with chronic inflammatory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International8trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Endomed s.r.o.
lock Showing 1 of 40 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics with Multiple Therapies in Participants with Active Crohn’s Disease or Active Ulcerative Colitis (ASCEND-IBD) | Mirador Therapeutics Inc. | Phase II | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 8 | Unknown | 2019-10-19 | 2026-05-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
